News Releases

Date	Title and Summary	View
Oct 15, 2021	Janssen Receives Positive CHMP Opinion for RYBREVANT® (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy
Oct 15, 2021	OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health CanadaApproved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)
Oct 15, 2021	Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
Oct 14, 2021	Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims
Oct 13, 2021	Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals
Oct 13, 2021	New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis
Oct 12, 2021	Johnson & Johnson to Participate in the Credit Suisse 30th Annual Healthcare Conference
Oct 12, 2021	Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021
Oct 11, 2021	Johnson & Johnson to Participate in the Credit Suisse 30th Annual Healthcare Conference
Oct 08, 2021	Janssen Submits Application Seeking U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis